Oral Administration of Recombinant Lactic Acid Bacteria Delivering Antiproteases at the Mucosal Level Protects Mice from Colitis L.L
Total Page:16
File Type:pdf, Size:1020Kb
Oral administration of recombinant lactic acid bacteria delivering antiproteases at the mucosal level protects mice from colitis L.L. Martin, Jean-Paul Motta, Luis Bermudez Humaran, Pascale Kharrat, J. -M. Sallenave, Philippe Langella, Nathalie Vergnolle To cite this version: L.L. Martin, Jean-Paul Motta, Luis Bermudez Humaran, Pascale Kharrat, J. -M. Sallenave, et al.. Oral administration of recombinant lactic acid bacteria delivering antiproteases at the mucosal level protects mice from colitis. 10. World Congress on Inflammation, Jun 2011, Paris, France. pp.S80, 10.1007/s00011-011-0341-6. hal-01001507 HAL Id: hal-01001507 https://hal.archives-ouvertes.fr/hal-01001507 Submitted on 3 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Inflamm. Res. (2011) 60 (Suppl 1):S1–S321 DOI 10.1007/s00011-011-0341-6 Inflammation Research The 10th World Congress on Inflammation 25–29 June 2011 Palais des Congre`s (Paris, France) The Abstracts 123 S2 Inflamm. Res. Committees & Boards Congress Chairman Neville Punchard (UK) William Selig (USA) Michel Chignard (Paris, France) John Somerville (USA) Mauro Teixeira (Brazil) Vice Chairmen Boris Vargaftig (Brazil) Graham Wallace (UK) Charles Brink (IAIS, Awards) Francis Berenbaum (Local Scientific Committee) International advisory board Vincent Lagente (Local Organizing Committee) Masayuki Amagai (Japan) Honorary Chair Michel Aubier (France) Vickie E. Baracos (Canada) B. Boris Vargaftig (Sao Paulo, Brazil) Maria G. Belvisi (UK) Pierre Borgeat (Canada) Susan Brain (UK) Local Organizing Committee Marco Cassatella (Italy) Jean-Marc Cavaillon (France) Claude Bertrand (Boulogne-Billancourt, France) Nadine Cerf-Bensoussan (France) Marie-The´re`se Corvol (Paris, France) Annick Cle´ment (France) Lise Halbwachs-Mecarelli (Paris, France) Anthony J. Coyle (USA) Vincent Lagente (Rennes, France) Leslie J. Crofford (USA) Xavier Norel (Paris, France) Fre´de´ric De Blay (France) Local Scientific Committee Elisabetta Dejana (Italy) Be´atrice Desvergne (Switzerland) Laurent Baud (Paris, France) Mary Dinauer (USA) Francis Berenbaum (Paris, France) Kate Fitzgerald (USA) Charles Brink (Paris, France) Nelly Frossard (France) Sylvie Chollet-Martin (Paris, France) Fre´de´ric Geissmann (UK) Jean-Yves Jouzeau (Nancy, France) Pierangelo Geppetti (Italy) Franc¸oise Pons (Strasbourg, France) Loı¨c Guillevin (France) Jean-Franc¸ois Savouret (Paris, France) Jiahuai Han (China) Mustapha Si-Tahar (Paris, France) Lars Klareskog (Sweden) Nathalie Vergnolle (Toulouse, France) Karl-Heinz Krause (Switzerland) Ve´ronique Witko-Sarsat (Paris, France) Toby Lawrence (UK) Peter Libby (USA) International Boards Isabelle Maridonneau-Parini (France) Kayo Masuko (Japan) IAIS officers and members Jason MacDougall (Canada) Jane A. Mitchell (UK) Lisa Marshall (USA), President Attila Mocsai (Hungary) John Rømer (Denmark), Vice President Mauro Perretti (UK) Vincent Lagente (France), Treasurer Dana Philpott (Canada) Ian M. Adcock (UK), Secretary Andrew Rees (Austria) Ian Ahnfelt-Rønne (Denmark) Adriano G. Rossi (UK) Michel Chignard (France) Jean-Michel Sallenave (France) John Di Battista (Canada) Abdelhadi Saoudi (France) Sergio Ferreira (Brazil) Caroline Savage (UK) John Hamilton (Australia) Charles Serhan (USA) Hans-Detlef Klueber (Switzerland) Hans Uwe Simon (Switzerland) Gordon Letts (USA) Martin Steinhoff (Germany) Kouji Matsushima (Japan) Peter Stenvinkel (Sweden) Tineke Meijers (Canada) Wim Van Den Berg (The Netherlands) Nobuyuki Miyasaka (Japan) John L. Wallace (Canada) Eric Morand (Australia) Cheryl Winckler (USA) Michael Parnham (Croatia) Arturo Zychlinsky (Germany) 123 Inflamm. Res. S3 Table of Content Keynote Lectures ....................................................................................S5 KL-01 Drosophila as a model system for inflammation.........................................................S5 KL-02 New therapeutic approaches in inflammation: the example of endogenous gas ...................................S5 KL-03 Metagenomics: impact on research in inflammation ......................................................S5 KL-04 Senescence and inflammation: new links, new targets . .................................................S6 KL-05 Development and modulation of IL-17 immune responses targets . .........................................S6 Educational Sessions ..................................................................................S6 EDUC1 Imaging technologies to investigate inflammatory immune responses .........................................S6 EDUC2 MicroRNAs as new players of inflammation . .........................................................S6 Symposia ..........................................................................................S7 SY01 News and goods to map and treat inflammatory bowel disease . .........................................S7 SY02 Adipokines new kids on the inflammation block .........................................................S8 SY03 New perspectives on T cells in inflammatory diseases .....................................................S9 SY04 Cell death...................................................................................S10 SY05 Inflammatory cells: neutrophils and macrophages .......................................................S11 SY06 Neuronal control of inflammation and pain............................................................S12 SY07 Rheumatoid arthritis: from pathophysiology to new targets ................................................S14 SY08 Cell signaling and communication. ...............................................................S15 SY09 Resolution and inflammatory concert . ...............................................................S16 SY10 Damps and pamps; critical endogenous and exogenous danger signals. ........................................S17 SY11 Vasculitis-autoimmunity. .......................................................................S18 SY12 Osteoarthritis . ..............................................................................S19 SY13 Yes, we have new opportunities for anti-inflammatory drug discovery. ........................................S20 Society Sponsored Symposia ...........................................................................S21 SP01 New pro- and anti- inflammatory effects of microbes.....................................................S21 SP02 Post-traumatic immune suppression . ...............................................................S23 SP03 Chemical toxicity and inflammation . ...............................................................S24 SP04 Bone inflammation and regeneration . ...............................................................S25 SP05 Cancer and inflammation . .......................................................................S25 SP06 Inflammation in severe sepsis: from bench to bedside ....................................................S26 SP07 New trends in the control of lung inflammation. ........................................................S28 SP08 Auto-inflammatory diseases.......................................................................S30 SP09 Translational research strategies in inflammation ........................................................S31 SP10 Genomics and epigenetics of inflammation ............................................................S32 SP11 Atherosclerosis: the role of inflammation .............................................................S32 SP12 Inflammation and repair in lung disease ..............................................................S33 Oral Communication Sessions ..........................................................................S38 OC01 Infection and inflammation.......................................................................S38 OC02 New therapeutic targets in inflammation .............................................................S41 OC03 Pain, neuroinflammation . .......................................................................S43 OC04 Cancer, genetics and inflammation . ...............................................................S46 OC05 Sepsis and inflammation . .......................................................................S53 OC06 Autoimmunity, connective tissue diseases ............................................................S56 OC07 Inflammatory cells recruitment and activation. ........................................................S59 OC08 Lipid mediators and metabolic diseases ..............................................................S62 OC09 Cytokines, cell signalling. .......................................................................S69 OC10 Inflammatory processes in cardiovascular and renal diseases . ........................................S72 OC11 Respiratory diseases ...........................................................................S75 OC12 Reactive oxygen species and proteases ..............................................................S78 Posters ...........................................................................................S83